Mini‐review: The nuclear protein HMGB1 as a proinflammatory mediator

European Journal of Immunology - Tập 34 Số 6 - Trang 1503-1512 - 2004
Helena Erlandsson Harris1, Jan Andersson2
1Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
2Department of Woman and Child Health, Astrid Lindgren Children's Hospital, Karolinska Institutet, Stockholm, Sweden.

Tóm tắt

AbstractThe intranuclear architectural protein that is termed high mobility group box chromosomal protein 1 (HMGB1) was recently identified as a potent proinflammatory mediator when present extracellularly. HMGB1 has been demonstrated to be a long‐searched‐for nuclear danger signal passively released by necrotic, as opposed to apoptotic, cells that will induce inflammation. Furthermore, HMGB1 can also be actively secreted by stimulated macrophages or monocytes in a process requiring acetylation of the molecule, which enables translocation from the nucleus to secretory lysosomes. Subsequenttransport out of the cells depends on a secretion signal mediated by either extracellular lysophophatidyl‐choline or ATP. HMGB1 passively released from necrotic cells and HMGB1 actively secreted byinflammatory cells are thus molecularly different. Extracellular HMGB1 acts as a cytokine by signaling via the receptor for advanced glycated end‐products and via members of the Toll‐like receptor family. The initiated inflammatory responses include the production of multiple cytokines, chemoattraction of certain stem cells, induction of vascular adhesion molecules and impaired function of intestinalepithelial cells. Therapeutic administration of HMGB1 antagonists rescues mice from lethal sepsis, even when initial treatment is delayed for 24 h after the onset of infection, establishing a clinically relevant therapeutic window that is significantly wider than for other known cytokines.

Từ khóa


Tài liệu tham khảo

10.1016/S0264-410X(02)00164-0

10.1101/SQB.1989.054.01.003

10.1016/0167-5699(92)90198-G

10.1146/annurev.iy.12.040194.005015

10.1016/S0165-2478(02)00228-6

10.1189/jlb.0203082

10.1038/15200

10.1073/pnas.260497597

10.1002/1521-4141(200201)32:1<155::AID-IMMU155>3.0.CO;2-P

10.1038/nature00858

10.4049/jimmunol.166.12.7128

10.1016/S1359-6101(97)00023-3

10.1038/nri1200

10.1189/jlb.0703328

10.1038/74697

10.1038/nature01991

10.1126/science.285.5425.248

10.1084/jem.192.4.565

10.1111/j.1432-1033.1973.tb03026.x

10.1128/MCB.19.8.5237

10.1016/S0959-437X(03)00023-6

10.1093/nar/15.21.9077

10.1093/nar/17.3.1197

10.1083/jcb.107.6.2293

10.1006/geno.1996.0369

10.1007/BF03402105

10.1038/10338

10.1016/S0039-128X(99)00036-7

10.1074/jbc.M110400200

10.1101/gad.12.4.462

10.1016/S0092-8674(00)80181-6

10.1073/pnas.100108697

10.1083/jcb.137.1.19

10.1093/emboj/cdg516

10.1126/science.8178167

10.1111/j.1365-2796.2003.01296.x

10.1073/pnas.78.10.5988

10.1074/jbc.270.43.25752

10.1074/jbc.274.28.19919

Rouhiainen A., 2000, Occurrenceof amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation., Thromb. Haemost., 84, 1087, 10.1055/s-0037-1614175

Parkkinen J., 1993, Amphoterin, the 30‐kDa protein in a family of HMG1‐type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation., J. Biol. Chem., 268, 19726, 10.1016/S0021-9258(19)36575-5

10.1042/0264-6021:3630529

10.1093/embo-reports/kvf198

10.1016/S0039-6060(99)70182-0

10.1042/0264-6021:3570569

10.1006/cyto.2002.1948

10.1097/00024382-200204000-00016

10.1016/S0167-4889(00)00087-2

10.1038/35012626

10.1083/jcb.152.6.1197

10.2144/97224rr01

10.1046/j.1365-2796.2003.01204.x

10.1083/jcb.200304135

10.1074/jbc.M306793200

10.1152/ajpcell.00322.2002

10.1182/blood-2002-05-1300

10.4049/jimmunol.165.6.2950

10.1002/art.11028

10.1203/00006450-200208000-00004

10.1093/nar/21.15.3427

10.1002/j.1460-2075.1993.tb05776.x

10.1073/pnas.2434651100

10.1016/S0140-6736(99)02658-6

10.1016/j.cyto.2003.08.001

10.1002/art.10540

10.1002/art.10859

Ulfgren A.‐K., 2004, Cortocosteroid‐therapy downregulates the proinflammatory mediator HMGB1 in myositis patients., Arthritis Rheum.

10.1097/00024382-199508000-00002

10.1038/72262

10.1002/art.11161

10.1073/pnas.192222999

10.1152/ajpgi.00022.2002

10.1053/gast.2002.35391

Thông tin
Thông tin xuất bản

European Journal of Immunology

Tập 34 Số 6

1503-1512

Thông tin tác giả